Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9873740
SERIAL NO

14333375

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • GENENTECH, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bowles, Kristin South San Francisco, US 12 191
Comps-Agrar, Laetitia Foster City, US 9 137
Eaton, Dan San Rafael, US 14 278
Grogan, Jane San Francisco, US 17 262
Hackney, Jason San Carlos, US 14 182
Irving, Bryan San Francisco, US 33 1052
Johnston, Robert J San Francisco, US 59 515
Yu, Xin South San Francisco, US 196 1185

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 23, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 23, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00